Skip to main content
OpenTrials
Completed

NCT Number: NCT03463694

Edinburgh and Lothian Virus Intervention Study in Kids

ELVIS Kids is a parallel, open label, randomised controlled trial (RCT) of Hypertonic Saline (HS) nose drops (~2.6% NaCl) vs. standard care in children <7 years of age with symptoms of an Upper Respiratory Tract Infection (URTI).

Completed

Looking for future studies?

Notify Me

Key information

About this study

The study will run over ~30 months. Children are recruited prior to, or within 48 hours of developing URTI symptoms by advertising in areas such as local schools, nurseries, health centres and workplaces as well as social media. For the purposes of this study an URTI is defined as: at least two respiratory symptoms (nasal stuffiness, runny nose, cough, sore throat, or sneezing) OR one respiratory symptoms and at least one systemic symptom (lethargy, muscle pain, headache, pyrexia ≥38°C).

Willing parents/guardians, of children <7 years of age, will be directed by the study advertising to contact the research team at their local research site if they are interested in participating. Children will be randomised to either a Control arm of standard symptomatic care, or an Intervention arm of 3 drops each nostril of HS at least 4 times a day until 24 hours after asymptomatic or maximum of 28 days. All participants will be requested to obtain a mid-turbinate nasal swab prior to first nasal HS drops (repeated daily for 5 days), a daily symptom diary (CARIFS, a valid illness measure in the UK), and an end of illness questionnaire (healthcare use, adverse events, acceptability, infection in household contacts, parental time taken off usual activities). Parent/guardian of the children allocated to the intervention arm will be taught how to prepare the HS. Parent/guardian of children who are asymptomatic at recruitment are requested to inform CCRF when the child develops an URTI (within 48 hours) and follow the instructions already provided to them when given the go-ahead to start the trial. On day 28, parents/guardians will be contacted to determine if their child suffered from wheeze either during the illness or at any point until day 28. Participation in the study will end on day 28.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Children between corrected gestational age of ≥40 weeks and <7 years of age
  • Children without URTI OR ≤48 hours of URTI* starting.
  • A URTI being defined as at least two respiratory symptoms (nasal congestion (i.e. stuffy nose), runny nose, cough, sore throat) OR one respiratory symptom + at least one systemic symptom (Low energy/tired, muscle aches/pains, headache, fever ≥38°C).

Exclusion criteria

  • Children needing immediate medical attention
  • Children using saline drops/sprays at the time of randomisation
  • Children on immunosuppressive medication, regular oral/inhaled steroids, regular antibiotics (use of antibiotics is allowed as long as the child does not need regular antibiotics)
  • Children with a known chronic illness (e.g. cystic fibrosis, cardiac, renal, liver, lung, neurological conditions) apart from wheeze or asthma which are not exclusions if the child is otherwise well and not on regular steroids)
  • Children being followed up for developmental delay
  • Children receiving the nasal flu vaccine ≤14 days ago
  • Children taking part in another interventional trial
  • If parents/guardians indicating that they are unable to comply with the study protocol prior to randomisation
  • If parents/guardians are unable to understand written or spoken English
  • Children randomised to ELVIS KIDS on a previous episode of URTI
  • Children with a concurrently participating sibling

Treatment and study plan

Na Cl solution

Other

~2.6% NaCl solution prepared from sea salt

Primary outcomes

  1. Time to the first report that the child is "not unwell".

    Time frame: Maximum of 28days

    Time until child not unwell

Secondary outcomes

  1. Severity of all symptoms

    Time frame: 1-28 days (or until child is well)

    Recorded by parents from options: No Problem, Minor Problem,Moderate Problem,Major Problem or Unknown/Not Applicable

  2. The length of time for individual symptoms to resolve

    Time frame: 1-28 days (or until child is well)

    Recorded as: No Problem, Minor Problem,Moderate Problem,Major Problem or Unknown/Not Applicable

  3. Severity of individual symptoms

    Time frame: 1-28 days (or until child is well)

    Recorded by parents from options: No Problem, Minor Problem,Moderate Problem,Major Problem or Unknown/Not Applicable

  4. Contacting healthcare (NHS 24, OOH, GP) -Number of participants

    Time frame: 1-28 days (or until child is well)

    Number of participants

  5. Contacting healthcare (NHS 24, OOH, GP) -Frequency of contacts

    Time frame: 1-28 days (or until child is well)

    Number of contacts

  6. Participants needing GP appointments- Number of participants

    Time frame: 1-28 days (or until child is well)

    Number of appointments

  7. Participants needing GP appointments- Frequency of contacts

    Time frame: 1-28 days (or until child is well)

    Number of appointments

  8. Number of participants attending hospital and diagnosis - Number of participants

    Time frame: 1-28 days (or until child is well)

    Number of participants

  9. Number of participants attending hospital and diagnosis - Frequency of contacts

    Time frame: 1-28 days (or until child is well)

    Number of attendances

  10. Length of stay in hospital if admitted

    Time frame: 1-28 days (or until child is well)

    Length in Days

  11. Number of participants reporting wheeze during illness and between end of illness to 28 days

    Time frame: Day 28

    Number reporting wheeze

  12. Number of participants reporting over the counter medication use

    Time frame: 1-28 days (or until child is well)

    Number of participants

  13. Duration of viral shedding

    Time frame: Days 1-5

    Viral shedding duration in days

  14. Reduction in viral shedding

    Time frame: Days 1-5

    Log conversion of each positive result will be done using the following formula: (40-CT of specimen)/3.3 to estimate change in shedding.

  15. Rate of reduction in viral shedding

    Time frame: Days 1-5

    Rate of viral shedding duration in days

  16. Reduction in transmission to household contacts

    Time frame: 1-28 days (or until child is well)

    Questionnaire - reported number of adults and children catching URTI

  17. Number of participants reporting side effects of nasal drops

    Time frame: 1-28 days (or until child is well)

    Side effects reported

  18. Types and severity of side effects reported

    Time frame: 1-28 days (or until child is well)

    Side effects reported

  19. Number of days lost from school/nursery for child

    Time frame: 1-28 days (or until child is well)

    Number of days

  20. Number of days lost from work for parent/guardian

    Time frame: 1-28 days (or until child is well)

    Number of days

  21. Cost of over the counter medication used

    Time frame: 1-28 days (or until child is well)

    Cost of medicine used.

Sponsors and collaborators

Lead sponsor

University of Edinburgh

Other

Registry information

Official study title

Edinburgh and Lothian Virus Intervention Study in Kids (ELVIS Kids): A Randomised Controlled Trial of Hypertonic Saline Nose Drops in Children With Upper Respiratory Tract Infections

Acronym: ELVIS Kids

Important dates

Study start
2018
Primary completion
2023
Study completion
2023
First posted
Mar 13, 2018
Registry last updated
May 17, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.